• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting

    6/2/25 7:00:00 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZLAB alert in real time by email

    - Clinically meaningful anti-tumor activity of ZL-1310 observed in heavily pretreated population of patients with small cell lung cancer (SCLC) across dose escalation and expansion cohorts

    - In second-line (2L) SCLC, objective response rate (ORR) was 67% across all dose levels (n=33) and 79% at 1.6 mg/kg dose (n=14)

    - Median duration of response has not yet been reached, with 29 of 38 responders remaining on study; 27 of 31 patients with stable disease remaining on study, the majority of whom had tumor regressions

    - ZL-1310 demonstrated a well-tolerated safety profile at target doses of less than 2.0 mg/kg, with Grade ≥3 treatment-related adverse events (TRAEs) of 6%, and no drug discontinuations

    - Company plans to initiate pivotal trial in 2L SCLC with selected optimal dose later this year

    - Zai Lab to host investor conference call and webcast to discuss data and clinical trial plans on June 2, 2025, at 7:00 a.m. CT / 8:00 a.m. ET / 8:00 p.m. HKT

    Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced that updated data from an ongoing, global Phase 1a/1b clinical trial (NCT06179069) evaluating zocilurtatug pelitecan, or ZL-1310, the Company's potential first-in-class, Delta-like ligand (DLL3) antibody-drug conjugate (ADC) for patients with extensive-stage small cell lung cancer (ES-SCLC), will be presented today during a poster session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentation includes updated results from the dose escalation portion and the first presentation of dose expansion data from a total of 89 enrolled patients across six dose cohorts.

    "Small cell lung cancer is an aggressive disease, with rapid disease progression and brain metastases developing in up to 70% of patients," said Manish R. Patel, M.D., Florida Cancer Specialists and Sarah Cannon Research Institute. "There remains a significant unmet need for effective and well-tolerated therapies in the relapsed setting. The updated Phase 1 results for ZL-1310 show strong anti-tumor activity, including intracranial responses with a manageable safety profile, reinforcing its potential as a meaningful treatment option for patients with previously treated extensive-stage small cell lung cancer."

    Data from the ongoing Phase 1 monotherapy dose escalation and dose expansion portion of the study as of the data cut-off date of April 1, 2025, include results from 89 patients across six dose cohorts (0.8 mg/kg, 1.2 mg/kg, 1.6 mg/kg, 2.0 mg/kg, 2.4 mg/kg and 2.8 mg/kg). 74 patients had at least one post-baseline tumor assessment per RECIST v1.1.

    All patients in the study had progressed following platinum-based chemotherapy, and 90% of patients had progressed after immune checkpoint inhibitors. Of all patients, 33% had failed two prior lines of therapy, and 20% had failed three or more prior lines of therapy, making this a highly pretreated population with limited therapeutic options. 10 patients received a prior DLL3 bi-specific antibody. A total of 30% of patients had brain metastases at baseline. This study included patients in the United States, Europe and China.

    Key efficacy results include (n=74):

    • Across all dose levels in the 2L treatment setting (n=33), the unconfirmed objective response rate (uORR) in patients was 67% and the disease control rate (DCR) was 97%. The most promising combination of response and tolerability was observed in the 1.6 mg/kg arm (n=14) with a uORR of 79% and a DCR of 100%.



    • Across all doses and lines of therapy (n=74), of 38 patients with confirmed (n=27) and unconfirmed (n=11) ORR, 29 (76%) remain on study, with the longest responder surpassing nine months of treatment. Eighty-nine percent of patients experienced a reduction in their tumor burden. Of the 31 patients with stable disease, 27 (87%) remain on study.



    • Response rates declined with increased prior treatment burden and higher dose levels, consistent with more advanced disease and potential tolerability limitations above 2.0 mg/kg.



    • Of the 22 response-evaluable patients with baseline brain metastases, a 68% ORR was observed. In patients without prior cranial irradiation, ORR was 86%.



    • Responses were seen in patients following treatment with a prior DLL3 bi-specific across lines of therapy.



    • Median length of follow-up is immature at 3.4 months, making median duration of response not estimable.

    Key safety findings include (n=89):

    • ZL-1310 continues to demonstrate a well-tolerated safety profile, particularly in doses less than 2.0 mg/kg.



    • In the dose cohort <2.0 mg/kg, Grade 3 or higher TRAEs occurred in 6% of patients and serious TRAEs in 4%. The most common TRAEs were anemia (Gr≥3 2%) and neutropenia (Gr≥3 4%). There were no treatment discontinuations and no Gr≥3 interstitial lung diseases (ILDs).



    • Across all dose cohorts, Grade 3 or higher TRAEs occurred in 23% of patients and serious TRAEs in 21%. The most common TRAEs were anemia (Gr≥3 11%) and neutropenia (Gr≥3 14%). There were five discontinuations due to TRAEs, all in the higher dose cohort. There were two cases of Gr≥3 treatment-related ILD, one at the 2.0 g/kg dose and one at the 2.4 mg/kg dose.

    Based on the safety and efficacy data from this trial, Zai Lab plans to initiate a randomized registrational study in 2L ES-SCLC later this year, evaluating the selected dose of ZL-1310 versus standard of care. Zai Lab is also actively enrolling patients in a front-line SCLC study and in other neuroendocrine carcinomas, with data updates anticipated later this year.

    "The safety and efficacy profile of ZL-1310 continues to highlight a compelling opportunity to significantly improve the outcomes for patients with extensive-stage small cell lung cancer and underscores its potential to become the first-in-class DLL3-targeted ADC in this setting," said Rafael G. Amado, M.D., President, Head of Global Research and Development, Zai Lab. "We are continuing to advance a clear strategy to expand the reach of ZL-1310 across multiple high-need DLL3-expressing solid tumor types, with our first regulatory submission targeted as early as next year."

    Zai Lab will hold an investor conference call and webcast to highlight updated ZL-1310 data at ASCO and outline the next steps in clinical development.

    Details regarding the webcast and conference call are as follows:

    Date/Time: Monday, June 2, 2025, at 7:00 a.m. CT / 8:00 a.m. ET / 8:00 p.m. HKT, please register at:

    Webcast presentation (preferred): https://edge.media-server.com/mmc/p/jnqqzjod

    Dial-in: https://register-conf.media-server.com/register/BIc7326906f3764306accd7708d21d2ecb

    Presenters: Rafael G. Amado, M.D., President, Head of Global Research and Development, Zai Lab; Manish R. Patel, M.D., Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL; and Alex Spira, M.D., Ph.D., Co-Director, Virginia Cancer Specialists Research Institute

    Details regarding the ZL-1310 poster presentation are as follows:

    Title: ZL-1310, a DLL3 ADC, in patients with extensive stage small cell lung cancer: Ph1 trial update

    Presenter: Manish R. Patel, M.D., Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL

    Session Title: Poster Session – Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology

    Date/Time: Monday, June 2, 2025, from 1:30 p.m. – 4:30 p.m. CT

    Location: McCormick Place Convention Center, Hall A – Posters and Exhibits

    Published Abstract Number: 3041

    Poster Board: 356

    About Small Cell Lung Cancer and ZL-1310

    Small cell lung cancer (SCLC) is one of the most aggressive and lethal solid tumors, accounting for ~15% of the approximately 2.5 million patients diagnosed with lung cancer worldwide each year1,2. Additionally, two-thirds of all SCLC patients are diagnosed at extensive stage3.

    DLL3 is an antigen overexpressed in many neuroendocrine tumors, such as SCLC, and is often associated with poor clinical outcomes. ZL-1310 comprises a humanized anti-DLL3 monoclonal antibody connected via a cleavable linker to a novel camptothecin derivative (a topoisomerase 1 inhibitor) as its payload. The compound was designed with a novel ADC technology platform called TMALIN®, which leverages the tumor microenvironment to overcome challenges associated with first-generation ADC therapies.

    ZL-1310 received an Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in January 2025, recognizing its potential to treat patients with SCLC.

    About the Webcast and Conference Call

    All participants must use the link provided above to complete the online registration process in advance of the conference call. Dial-in details will be in the confirmation email which the participant will receive upon registering.

    A replay will be available shortly after the call and can be accessed by visiting the Company's website.

    About Zai Lab

    Zai Lab (NASDAQ:ZLAB, HKEX: 9688)) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience and infectious disease. Our goal is to leverage our competencies and resources to positively impact human health worldwide.

    For additional information about Zai Lab, please visit www.zailaboratory.com or follow us at www.X.com/ZaiLab_Global, www.twitter.com/ZaiLab_Global.

    Zai Lab Forward-Looking Statements

    This press release contains forward-looking statements relating to our future expectations, plans, and prospects, for Zai Lab, including, without limitation, statements relating to our prospects and plans for developing and commercializing next generation ADCs, including ZL-1310, the potential benefits of ZL-1310, and the potential treatment of SCLC and neuroendocrine tumors. These forward-looking statements may contain words such as "aim," "anticipate," "believe," "could," "estimate," "expect," "forecast," "goal," "intend," "may," "plan," "possible," "potential," "will," "would," and other similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact or guarantees or assurances of future performance. Forward-looking statements are based on our expectations and assumptions as of the date of this press release and are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including but not limited to (1) our ability to successfully commercialize and generate revenue from our approved products, (2) our ability to obtain funding for our operations and business initiatives, (3) the results of our clinical and pre-clinical development of our product candidates, (4) the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of our product candidates, (5) risks related to doing business in China, and (6) other factors identified in our most recent annual and quarterly reports and in other reports we have filed with the U.S. Securities and Exchange Commission (SEC). We anticipate that subsequent events and developments will cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

    Our SEC filings can be found on our website at www.zailaboratory.com and on the SEC's website at www.sec.gov.

    References:

    1 J Thorac Oncol. 2023 Jan;18(1):31-46; Lung Cancer Foundation of America.

    2 WHO Globocan 2022.

    3 Sabari JK, et al. Nat Rev Clin Oncol. 2017;14:549-561.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250602617824/en/

    For more information:

    Investor Relations:

    Christine Chiou / Lina Zhang

    +1 (917) 886-6929 / +86 136 8257 6943

    [email protected] / [email protected]

    Media:

    Shaun Maccoun / Xiaoyu Chen

    +1 (857) 270-8854 / +86 185 0015 5011

    [email protected] / [email protected]

    Get the next $ZLAB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ZLAB

    DatePrice TargetRatingAnalyst
    3/7/2025$55.00Sector Outperform
    Scotiabank
    3/3/2025$29.00 → $36.10Buy → Neutral
    BofA Securities
    12/14/2023$47.50Overweight
    Morgan Stanley
    8/10/2023$70.00Overweight
    Cantor Fitzgerald
    3/2/2022$194.00 → $102.00Outperform
    SVB Leerink
    1/21/2022$64.00Outperform
    Macquarie
    12/15/2021$189.00 → $136.00Overweight
    JP Morgan
    11/11/2021$222.00 → $217.00Buy
    Citigroup
    More analyst ratings

    $ZLAB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chairperson & CEO Du Ying exercised 96,389 units of American Depositary Shares at a strike of $0.60 and sold $2,731,507 worth of American Depositary Shares (96,389 units at $28.34) (SEC Form 4)

      4 - Zai Lab Ltd (0001704292) (Issuer)

      5/15/25 4:27:50 PM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Morrison Scott W sold $715,086 worth of American Depositary Shares (23,799 units at $30.05), decreasing direct ownership by 50% to 23,702 units (SEC Form 4)

      4 - Zai Lab Ltd (0001704292) (Issuer)

      5/13/25 4:48:29 PM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chairperson & CEO Du Ying exercised 100,000 units of American Depositary Shares at a strike of $0.60 and sold $2,953,308 worth of American Depositary Shares (100,000 units at $29.53) (SEC Form 4)

      4 - Zai Lab Ltd (0001704292) (Issuer)

      5/13/25 4:48:13 PM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZLAB
    Financials

    Live finance-specific insights

    See more
    • Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting

      - Clinically meaningful anti-tumor activity of ZL-1310 observed in heavily pretreated population of patients with small cell lung cancer (SCLC) across dose escalation and expansion cohorts - In second-line (2L) SCLC, objective response rate (ORR) was 67% across all dose levels (n=33) and 79% at 1.6 mg/kg dose (n=14) - Median duration of response has not yet been reached, with 29 of 38 responders remaining on study; 27 of 31 patients with stable disease remaining on study, the majority of whom had tumor regressions - ZL-1310 demonstrated a well-tolerated safety profile at target doses of less than 2.0 mg/kg, with Grade ≥3 treatment-related adverse events (TRAEs) of 6%, and no drug disc

      6/2/25 7:00:00 AM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zai Lab Receives U.S. FDA Fast Track Designation for ZL-1310, a DLL3-Targeted Antibody-Drug Conjugate, for Treatment of Extensive-Stage Small Cell Lung Cancer

      - The Company is on track to initiate a pivotal study for ZL-1310 in small cell lung cancer (SCLC) in 2025 Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ZL-1310, the Company's potential first-in-class Delta-like ligand (DLL3) antibody-drug conjugate (ADC), for the treatment of extensive-stage small cell lung cancer (ES-SCLC). ZL-1310, which is being evaluated in an ongoing global Phase 1a/1b clinical trial (NCT06179069), previously received an Orphan Drug designation for SCLC from the FDA. The company will present updated data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meetin

      5/19/25 7:00:00 AM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zai Lab Announces First Quarter 2025 Financial Results and Recent Corporate Updates

      – Total revenues grew 22% y-o-y to $106.5 million for the first quarter of 2025; reaffirming full-year 2025 revenue guidance of $560 million to $590 million – Operating loss improved significantly, declining 20% year-over-year to $56.3 million for the first quarter of 2025, and 25% to $37.1 million on an adjusted basis1; on track to achieve profitability1 in the fourth quarter of 2025 – ZL-1310 (DLL3 ADC) is advancing rapidly, with upcoming ASCO 2025 data presentation in ES-SCLC; initiation of registrational study in ES-SCLC expected in the second half of 2025 – AACR 2025 presentations of ZL-6201 (LRRC15 ADC) and ZL-1222 (PD-1/IL-12) underscore the promising potential of Zai Lab's intern

      5/8/25 6:00:00 AM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZLAB
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Zai Lab Limited

      SCHEDULE 13G/A - Zai Lab Ltd (0001704292) (Subject)

      5/14/25 10:39:54 AM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Zai Lab Limited

      SCHEDULE 13G/A - Zai Lab Ltd (0001704292) (Subject)

      5/12/25 10:44:44 AM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Zai Lab Limited

      144 - Zai Lab Ltd (0001704292) (Subject)

      5/9/25 11:35:52 AM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZLAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Zai Lab Limited

      SC 13G - Zai Lab Ltd (0001704292) (Subject)

      11/14/24 11:11:39 AM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Zai Lab Limited

      SC 13G/A - Zai Lab Ltd (0001704292) (Subject)

      11/8/24 10:52:38 AM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Zai Lab Limited (Amendment)

      SC 13G/A - Zai Lab Ltd (0001704292) (Subject)

      6/6/24 9:54:34 AM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZLAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Scotiabank initiated coverage on Zai Lab with a new price target

      Scotiabank initiated coverage of Zai Lab with a rating of Sector Outperform and set a new price target of $55.00

      3/7/25 8:00:31 AM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zai Lab downgraded by BofA Securities with a new price target

      BofA Securities downgraded Zai Lab from Buy to Neutral and set a new price target of $36.10 from $29.00 previously

      3/3/25 7:38:45 AM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley initiated coverage on Zai Lab with a new price target

      Morgan Stanley initiated coverage of Zai Lab with a rating of Overweight and set a new price target of $47.50

      12/14/23 7:54:36 AM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZLAB
    Leadership Updates

    Live Leadership Updates

    See more
    • Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D

        Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) announced today that following a distinguished career, Harald Reinhart, M.D., President, Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases (NSAiID) of Zai Lab, will retire at the end of June, after which he will serve as a senior advisor for the Company. Rafael Amado, M.D., President, Head of Global Oncology Research and Development of Zai Lab, will expand his role and assume responsibility for all of the Company's Global R&D upon Dr. Reinhart's retirement. "Harald has devoted nearly 50 years to treating patients, first as a physician and later discovering and developing innovative therapies to bring to patients in

      6/11/24 4:05:00 PM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zai Lab Appoints Michel Vounatsos To Its Board of Directors

      SHANGHAI and CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) today announced that Michel Vounatsos has been appointed to its Board of Directors, effective January 7, 2023. Mr. Vounatsos brings to the Board extensive global leadership and management experience in the biopharmaceutical industry, including more than 25 years of service at leading companies. His expertise includes significant commercial experience in China and worldwide in the areas of primary care and neuroscience. "We are delighted to welcome Michel Vounatsos to the Zai Lab Board of Directors," said Dr. Samantha Du, Founder, Chairperson, and CEO of Zai Lab. "Michel has a wealt

      1/9/23 7:30:00 AM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zai Lab Announces the Appointment of Dr. Rafael G. Amado as President, Head of Global Oncology Research and Development

      SHANGHAI and CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced the appointment of Rafael G. Amado, M.D. as President, Head of Global Oncology Research and Development, effective December 30, 2022. Dr. Amado brings to Zai Lab deep expertise in the field of oncology and significant global biopharmaceutical R&D leadership. "We are pleased to welcome Rafael to our executive leadership team," said Dr. Samantha Du, Founder, Chairperson, and CEO of Zai Lab. "Rafael's experience leading worldwide discovery and clinical development for a number of oncolog

      1/3/23 8:30:00 AM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZLAB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting

      - Clinically meaningful anti-tumor activity of ZL-1310 observed in heavily pretreated population of patients with small cell lung cancer (SCLC) across dose escalation and expansion cohorts - In second-line (2L) SCLC, objective response rate (ORR) was 67% across all dose levels (n=33) and 79% at 1.6 mg/kg dose (n=14) - Median duration of response has not yet been reached, with 29 of 38 responders remaining on study; 27 of 31 patients with stable disease remaining on study, the majority of whom had tumor regressions - ZL-1310 demonstrated a well-tolerated safety profile at target doses of less than 2.0 mg/kg, with Grade ≥3 treatment-related adverse events (TRAEs) of 6%, and no drug disc

      6/2/25 7:00:00 AM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

      TTFields therapy concomitant with gemcitabine and nab-paclitaxel is the first treatment to show a clinically meaningful and statistically significant improvement in overall survival (OS) for patients with unresectable, locally advanced pancreatic adenocarcinoma in a Phase 3 trial The OS benefit observed with TTFields therapy is supported by significantly improved quality of life and extended pain-free survival, a key outcome for patients with pancreatic cancer Results from PANOVA-3 accepted as a late-breaking abstract for oral presentation at ASCO and simultaneous publication in the Journal of Clinical Oncology Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) and Novocure (NASDAQ:NVCR)

      5/31/25 3:08:00 PM ET
      $NVCR
      $ZLAB
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Zai Lab Announces Participation in Investor Conferences in June 2025

      Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced that members of the Company's senior management team will participate in the following investor conferences in June 2025: Jefferies Global Healthcare Conference Fireside Chat: Wednesday, June 4, 2025, 10:30 a.m. EST Webcast Link: https://wsw.com/webcast/jeff319/zlab/1845848 Location: New York, NY Goldman Sachs 46th Annual Healthcare Conference Time: Monday, June 9, 2025 Location: Miami, FL Scotiabank Third Annual Healthcare Canadian Investor Day Time: Tuesday, June 17, 2025 Location: Toronto, Canada A live webcast of the fireside chat will be available on the Investor Relations page of Zai Lab's website at ir.zailaboratory.

      5/30/25 7:30:00 AM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ZLAB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Smiley Joshua L bought $64,200 worth of American Depositary Shares (3,000 units at $21.40), increasing direct ownership by 10% to 31,684 units (SEC Form 4)

      4 - Zai Lab Ltd (0001704292) (Issuer)

      5/15/24 4:03:12 PM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Smiley Joshua L bought $62,490 worth of American Depositary Shares (3,000 units at $20.83), increasing direct ownership by 15% to 23,527 units (SEC Form 4)

      4 - Zai Lab Ltd (0001704292) (Issuer)

      3/4/24 4:28:34 PM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Smiley Joshua L bought $119,600 worth of American Depositary Shares (4,000 units at $29.90), increasing direct ownership by 24% to 20,527 units (SEC Form 4)

      4 - Zai Lab Ltd (0001704292) (Issuer)

      12/18/23 5:08:48 PM ET
      $ZLAB
      Biotechnology: Pharmaceutical Preparations
      Health Care